Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. The phase 3 study is evaluating the candidate, dubbed mRNA-1403 ...

(Bloomberg) -- Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled manufacturing contract. The Cambridge, Massachusetts-based ...

Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past year, due to fading vaccine demand and pipeline uncertainty.

Moderna posted a Q4 EPS loss of $(2.91), missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological side effect was reported. The trial of the ...

General Mills, a multinational food company, is bringing one-of-its-kind pizza noodles for its frozen pizza brand Totino's. According to Allrecipes, Totino's Pizza Rolls is set to introduce Ramen ...

Moderna (NASDAQ:MRNA) is scheduled to announce Q4 earnings results on Friday, February 14th, before market open. Analysts expect a loss of $2.73 on revenue of $941.14M (-66.5% Y/Y). According to ...

Moderna shares fell more than 5% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine.